BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

AbSci

AbSci logo

Website
https://www.absci.com/
Founded
2011
Patents
20
Publications
12

Technologies

Antibody Discovery Companies

AbSci is a global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry. AbSci’s technology enables dramatic reductions in the cost of producing novel and existing biologics, acceleration of drug discovery timelines, and increased efficiency and flexibility throughout the manufacturing process.


Posts Mentioning This Company

AbSci and Other AI-Powered Biotechs Lead the Way in Antibody Discovery

April 1, 2023  
The monoclonal antibodies (mAbs) market has seen impressive growth in recent years, with the top-selling drugs increasingly being mAbs. The success of these therapeutics has driven the pharma industry to seek innovative methods for refining and improving their antibody pipelines. Artificial intelligence (AI) and deep learning, which have already revolutionized …

A Parade of AI-driven Biotechs Going Public in 2020-2021

Sept. 24, 2021  
Over 2020-2021 we have seen a remarkable parade of artificial intelligence (AI), focused on discovering novel therapeutics, going public. This reflects a continuing interest in AI as a transformative technology for the pharmaceutical industry and increasing belief in the wave of technology-driven “neo-biotechs”. Here we list some notable companies which …
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

AbSci’s Integrated Drug Creation™ Platform

AbSci’s revolutionary synthetic biology platform technology offers fully-integrated, AI-assisted, de novo drug discovery and cell line development … in weeks

News

  • 2025-05-14
    Absci Doses First Participants in Phase 1 Trial of AI-Designed Antibody for IBD
  • 2024-02-21
    Absci Initiates IND-Enabling Studies for ABS-101, Aiming for Enhanced Anti-TL1A Antibody Therapy

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.